Search company, investor...


Founded Year



Angel | Alive

Total Raised


Last Raised

$780K | 1 yr ago

About Kinathera

Kinathera is a biotech that aims to develop unique series of newly patented, orally delivered small chemical molecules to treat patients suffering from immuno-inflammatory disorders. It aims to provide innovative treatment to patients suffering from immuno-inflammatory disorders in rare or orphan diseases such as scleroderma or lupus. The company was founded in 2015 and is based in Marseille France.

Headquarters Location

163 avenue de Luminy Bâtiment Béret-Delaage, Case 922



Missing: Kinathera's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Kinathera's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Kinathera Frequently Asked Questions (FAQ)

  • When was Kinathera founded?

    Kinathera was founded in 2015.

  • Where is Kinathera's headquarters?

    Kinathera's headquarters is located at 163 avenue de Luminy, Marseille.

  • What is Kinathera's latest funding round?

    Kinathera's latest funding round is Angel.

  • How much did Kinathera raise?

    Kinathera raised a total of $780K.

  • Who are the investors of Kinathera?

    Investors of Kinathera include Grand Delta Angels and Provence Business Angels.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.